Ocugen, Inc. Common Stock

OCGNNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
1.03 USD
↗ 0.02 (2.50%)🟢PRE MARKET (AS OF 08:49 AM EDT)
🟢Market: OPEN

OCGN is currently priced at $1.03. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (387.2%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 1, 2026.

Open?$1.01
High?$1.03
Low?$1.01
Prev. Close?$1.00
Volume?54.9K
Avg. Volume?7.3M
VWAP?$1.01
Rel. Volume?0.01x
Bid / Ask
Bid?$0.86 × 100
Ask?$1.16 × 100
Spread?$0.30
Midpoint?$1.01
Valuation & Ratios
Market Cap?339.1M
Shares Out?339.1M
Float?323.6M
Float %?95.4%
P/E Ratio?N/A
P/B Ratio?-20.48
EPS?-$0.19
Dividend?0.00%
Ex-Dividend?N/A
RelatedMRNAPFE
News
Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
116
Market Cap
339.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.ocugen.com
Listed
2014-12-03
Address
11 GREAT VALLEY PARKWAY
MALVERN, PA 19355
Phone: 484-328-4701
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
29
Short Sent.?
5
Piotroski F-Score?1/9Weak
Altman Z-Score?-5.25Distress
Confidence?70%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?32.78%Squeeze Risk
Short Interest?106.1M
Days to Cover?10.4
Free Float323.6M
Avg Daily Volume10.2M
Settlement Date2026-09-15
Financial Health
Current Ratio?0.80Weak
Quick Ratio?0.80Weak
Cash Ratio?0.75Adequate
Debt/Equity?-5.08Low
ValuationFAIRLY VALUEDvs 2 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
-20.48CHEAP▾
P/S?
Peers
33
S&P
3
71.05HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-6.4CHEAP▾
EV/Sales?
Peers
33
S&P
3
67.71HIGH▾
Returns & Efficiency
ROE?
Peers
100
S&P
97
387.2%STRONG▾
ROA?
Peers
50
S&P
3
-51.6%WEAK▾
Cash Flow & Enterprise
FCF?$-61022000
Enterprise Value?$323.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist